Treosulfan
Treosulfan is a bifunctional alkylating agent and pro-drug that is spontaneously converted at physiological pH to a diepoxide form that cross-links DNA strands, inhibiting DNA replication and inducing apoptosis in rapidly dividing cells. It is used as a conditioning regimen prior to allogeneic hematopoietic stem cell transplantation in adults and children with hematologic malignancies including leukemia and lymphoma, offering myeloablative and immunosuppressive effects with a potentially more favorable toxicity profile than busulfan. Its activity in myeloid and lymphoid malignancies with reduced organ toxicity compared to classic conditioning agents represents a clinical advantage.
الوزن الجزيئي
278,3000 g/mol
LogP
-2,20
TPSA
144,00 Ų
قاعدة ليبينسكي للخمسة
ناجح
المجالات العلاجية
Pharmacokinetics (PK)
Pharmacodynamics (PD)
البنية ثنائية الأبعاد
Cite this structure
Embed this structure
SMILES
CS(=O)(=O)OC[C@H](O)[C@@H](O)COS(C)(=O)=O
InChI
InChI=1S/C6H14O8S2/c1-15(9,10)13-3-5(7)6(8)4-14-16(2,11)12/h5-8H,3-4H2,1-2H3/t5-,6-/m0/s1
Molecular Formula
C6H14O8S2
HBD / HBA
2 / 8
الروابط القابلة للدوران
7
الذرات الثقيلة
16
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
الأسئلة الشائعة
Treosulfan is a bifunctional alkylating agent and pro-drug that is spontaneously converted at physiological pH to a diepoxide form that cross-links DNA strands, inhibiting DNA replication and inducing apoptosis in rapidly dividing cells. It is used as a conditioning regimen prior to allogeneic hematopoietic stem cell transplantation in adults and children with hematologic malignancies including leukemia and lymphoma, offering myeloablative and immunosuppressive effects with a potentially more favorable toxicity profile than busulfan. Its activity in myeloid and lymphoid malignancies with …
Yes, Treosulfan is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL455186. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 9882105. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="treosulfan"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/treosulfan/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/treosulfan/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/treosulfan/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="treosulfan"></drugfyi-drug>